Biogen Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Biogen Holds On, But Growth Slips Through Its Fingers
Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.
Biogen cut to neutral at Piper Sandler on Alzheimer’s headwinds
Piper Sandler downgraded Biogen (NASDAQ:BIIB) to neutral from overweight on Thursday, citing, among other things, the company ...
Hosted on MSN21d
Biogen Stock: Is BIIB Underperforming the Healthcare Sector?
Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, with a market cap of $21.9 billion, is a leading biotechnology ...
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
In order from steepest decline to narrowest, the five unloved were Intel ( INTC 1.68%), MongoDB ( MDB 0.72%), Biogen ( BIIB 1 ...
Denali Therapeutics' ALS drug fails in mid-to-late stage trial
Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...
Biogen Inc. stock underperforms Tuesday when compared to competitors
Biogen Inc. closed $119.28 below its 52-week high ($268.30), which the company reached on January 3rd.
Biogen (NASDAQ:BIIB) Stock Rating Lowered by StockNews.com
Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to ...
Yahoo Finance29d
Biogen cut at Jefferies as '2025 has a tough setup'
Investing.com -- Jefferies downgraded Biogen (NASDAQ:BIIB) from a Buy to Hold on monday, citing a challenging outlook for 2025. The firm slashed its price target for the stock to $180 from $250 ...
Biogen downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler downgraded Biogen (BIIB) to Neutral from Overweight with a price target of $138, down from $315, following a transfer of ...